Radiopharmaceuticals end to end
Pre-clinical to commercial, isotope strategy to dose handling. Bracken has worked across the radiopharma value chain in ways few firms can claim.
Whether you're scoping a radiopharmaceutical program, designing imaging endpoints into a trial, or sorting out regulatory and commercial strategy, Bracken is the deep, neutral expert across the value chain.
Chief Medical Officer, The Bracken Group
Physician-scientist and strategist with over two decades of leadership in medical affairs, clinical development, and radiopharmaceuticals. His work has been pivotal to the successful launch and commercialization of two industry-leading products.
From translational research at Stanford—where his work seeded two startups, five early-phase trials, and two co-authored patents—to Senior Medical Director, Head of Medical Affairs, and CMO roles spanning American, European, and Asian companies, Deepak brings a rare blend of clinical depth, regulatory fluency, and commercial expertise to every engagement.
Pre-clinical to commercial, isotope strategy to dose handling. Bracken has worked across the radiopharma value chain in ways few firms can claim.
Bracken's signature work: medical imaging as a regulated endpoint. Protocol design, central reading, dosimetry, and the operational realities of running it.
From IND through label to launch readiness. We help radiopharma teams sequence the regulatory and commercial work without losing the science.
Bracken's recent partnership with LabConnect expands the operational reach of radiopharmaceutical clinical trials, pairing Bracken's imaging and regulatory expertise with LabConnect's central-lab footprint.
Specific scope and joint capabilities to be finalized for SNMMI 2026 messaging.
LabConnect at SNMMI 2026: Booth #2535. Stop by both us and them on the floor.
On-site at the Los Angeles Convention Center, May 30 to June 2. Request a meeting and we'll confirm a time to connect on the floor.